Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

132.48 +0.07 (+0.05%)
Streaming Delayed Price Updated: 12:54 PM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
While some retail companies are still thriving, investors would be smart to steer clear of these consumer stocks to avoid. 
Via InvestorPlace
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first. 
Via Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
We also look at the "treasure hunt" economy. 
Via The Motley Fool
Analyzing NYSE:NVO's Dividend Potential.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) provides a good dividend, while having solid fundamentals. 
Via Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18. 
Via InvestorPlace
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
Overall revenue fell short in Q1. Lilly stock is set to cross a key level. 
Via Investor's Business Daily
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Viking Therapeutics Incredibly Undervalued?
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound. 
Via The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock. 
Via Chartmill
Why Novo Nordisk Topped the Market Today
It's not only spending its capital on developing new drugs. 
Via The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications. 
Via The Motley Fool
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem. 
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits. 
Via Benzinga
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
These stocks probably won't be getting much cheaper. 
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
3 Biotech Stocks Set to Double by 2028
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. 
Via InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. 
Via The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic... 
Via Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.